Turkey

 

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.

Turkish groups look for lira depreciation workarounds

The Turkish Lira has been consistently depreciating, losing three-quarters of its US dollar value in the last five years. HBI speaks with an operator source, as well as consultants and operators from Turkey, to find out their strategy to hedge against a worsening exchange rate.

Will record results for Synlab precipitate Cinven sale?

Almost a year after its IPO, lab giant Synlab has posted strong FY21 results bolstered by Covid, but not, it says, dependant on it. Management say extra cash will be used as a springboard for growth. Could it also lead to private equity majority shareholder Cinven selling its remaining interest?

Affidea sale – potential price and buyers

European imaging and cancer treatment provider Affidea is for sale according to multiple sources. HBI chats to an operator source to find about more about the sale and to speculate on price and purchasers.

Treatment, not terrorism: Medical machines threaten global security

Ageing cobalt-based radiation therapy machines pose a threat to global national security, and moves are afoot by the World Institute for Nuclear Security to see them decommissioned, replaced, and their active elements safely disposed of before they fall into terrorist hands.

Mitsui mulls buyout of $13bn IHH Healthcare

Japanese conglomerate Mitsui is considering a buyout and de-listing of IHH Healthcare, the $13.4bn-valued pan-Asian hospital operator in which it holds a 32% stake, according to reports. Its share price has declined in the last five years amidst perennial problems in Turkey and India.

Find Us